Managers / Q2 2021 · view latest →
HARBOURVEST PARTNERS LLC
CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707
Summary
Harbourvest Partners LLC reported $1.0B in U.S.-listed holdings across 51 positions for Q2 2021.
The portfolio is heavily concentrated: W alone accounts for 32.1% of reported value.
Compared with Q1 2021, the fund opened 16 new positions and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 86.8% · $908M
- Other · 13.0% · $135M
- ADR · 0.2% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MNDYMonday.com | NEW | +1.23M | 1.23M | +$275M | $275M |
| Bright Health Group, Inc. | NEW | +4.22M | 4.22M | +$72M | $72M |
| FTCHQFarfetch Ltd. | NEW | +442.7K | 442.7K | +$22M | $22M |
| WHDCactus, Inc. | NEW | +392.9K | 392.9K | +$14M | $14M |
| DELLDell, Inc. | NEW | +67.3K | 67.3K | +$7M | $7M |
| CVRXCVRx, Inc. | NEW | +213.5K | 213.5K | +$6M | $6M |
| UPSTUpstart Holdings, Inc. | NEW | +45.3K | 45.3K | +$6M | $6M |
| PGNYProgyny, Inc. | NEW | +47.4K | 47.4K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | WWayfair, Inc.history → | Common CLA | 32.05% | $335M | 1.06M |
| 2 | MNDYMonday.comhistory → | SHS | 26.24% | $275M | 1.23M |
| 3 | Solarwinds Corp. | Common | 12.01% | $126M | 7.44M |
| 4 | Bright Health Group, Inc. | Common | 6.92% | $72M | 4.22M |
| 5 | Evelo Biosciences, Inc. | Common | 4.02% | $42M | 3.06M |
| 6 | Rubius Therapeutics, Inc. | Common | 2.30% | $24M | 986.9K |
| 7 | FTCHQFarfetch Ltd.history → | Ordinary Shares CLA | 2.13% | $22M | 442.7K |
| 8 | WHDCactus, Inc.history → | Common CLA | 1.38% | $14M | 392.9K |
| 9 | KLDOKaleido BioSciences, Inc.history → | Common | 1.30% | $14M | 1.83M |
| 10 | Axcella Health, Inc. | Common | 1.08% | $11M | 2.81M |
| 11 | RLAYRelay Therapeutics, Inc.history → | Common | 1.04% | $11M | 296.4K |
| 12 | RBLXRoblox Corporation | Common CLA | 0.89% | $9M | 103.8K |
| 13 | LendingClub Corp. | Common | 0.89% | $9M | 513.4K |
| 14 | Inari Medical | Common | 0.79% | $8M | 88.6K |
| 15 | Sigilon Therapeutics, Inc. | Common | 0.76% | $8M | 740.7K |
| 16 | DELLDell, Inc. | Common CLC | 0.64% | $7M | 67.3K |
| 17 | CVRXCVRx, Inc. | Common | 0.57% | $6M | 213.5K |
| 18 | TWLOTwilio, Inc. | Common CLA | 0.55% | $6M | 14.6K |
| 19 | UPSTUpstart Holdings, Inc. | Common | 0.54% | $6M | 45.3K |
| 20 | Zuora, Inc. | Common | 0.49% | $5M | 299.0K |
| 21 | IBRXImmunityBio, Inc. | Common | 0.46% | $5M | 335.7K |
| 22 | PGNYProgyny, Inc. | Common | 0.27% | $3M | 47.4K |
| 23 | Spark Networks SE | Sponsored ADR | 0.25% | $3M | 501.0K |
| 24 | UUnity Software | Common | 0.23% | $2M | 21.9K |
| 25 | TENBTenable Holdings, Inc. | Common | 0.22% | $2M | 55.0K |
| 26 | Root, Inc. | Common CLA | 0.21% | $2M | 204.3K |
| 27 | PATHUiPath, Inc. | Common CLA | 0.21% | $2M | 31.8K |
| 28 | Eventbrite, Inc. | Common CLA | 0.19% | $2M | 106.1K |
| 29 | AFRMAffirm, Inc. | Common CLA | 0.18% | $2M | 28.1K |
| 30 | YEXTYext, Inc. | Common | 0.16% | $2M | 115.1K |
| 31 | ABCLAbCellera Biologics, Inc. | Common | 0.12% | $1M | 59.2K |
| 32 | Seres Therapeutics, Inc. | Common | 0.11% | $1M | 49.4K |
| 33 | NRIXNurix Therapeutics, Inc. | Common | 0.11% | $1M | 44.1K |
| 34 | ACVAACV Auctions, Inc. | Common CLA | 0.10% | $1M | 40.0K |
| 35 | Castlight Health, Inc. | Common CLB | 0.09% | $918,000 | 349.1K |
| 36 | PACBPacific Biosciences of California, Inc. | Common | 0.08% | $821,000 | 23.5K |
| 37 | Duck Creek Technologies, Inc. | SHS | 0.06% | $631,000 | 14.5K |
| 38 | CTMXCytomx Therapeutics, Inc. | Common | 0.05% | $501,000 | 79.2K |
| 39 | RPTXRepare Therapeutics, Inc. | Common | 0.04% | $460,000 | 14.7K |
| 40 | Trevena, Inc. | Common | 0.04% | $395,000 | 233.8K |
| 41 | Aligos Therapeutics, Inc. | Common | 0.04% | $383,000 | 18.8K |
| 42 | Jounce Therapeutics, Inc. | Common | 0.03% | $362,000 | 53.3K |
| 43 | BILLBill.com Holdings, Inc. | Common | 0.03% | $324,000 | 1.8K |
| 44 | OYSTOyster Point Pharma, Inc. | Common | 0.03% | $267,000 | 15.5K |
| 45 | PMVPPMV Pharmaceuticals | Common | 0.03% | $263,000 | 7.7K |
| 46 | Yumanity | Common | 0.02% | $257,000 | 22.0K |
| 47 | Epizyme, Inc. | Common | 0.02% | $205,000 | 24.7K |
| 48 | Ramaco Resources, Inc. | Common | 0.01% | $82,000 | 15.0K |
| 49 | NextCure, Inc. | Common | 0.01% | $81,000 | 10.0K |
| 50 | Rapt Therapeutics, Inc. | Common | 0.01% | $56,000 | 1.8K |
| 51 | HNRGHallador Energy Resources, Inc. | Common | 0.00% | $38,000 | 14.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $101M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $174M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $205M | 9 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $91M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $154M | 16 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $203M | 22 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $192M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $188M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $219M | 48 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $299M | 53 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $295M | 58 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $352M | 60 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $297M | 63 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $299M | 65 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $306M | 67 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $305M | 62 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $490M | 66 | May 26, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $782M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 56 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.0B | 51 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $746M | 44 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $256M | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $270M | 36 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $232M | 28 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $207M | 36 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $243M | 35 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $240M | 33 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $262M | 32 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $283M | 33 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $211M | 32 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.